{'fraction_non_alphanumeric': 0.02735562310030395, 'fraction_numerical': 0.0060790273556231, 'mean_word_length': 5.276190476190476, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].

This article reviews the current evidence of effects on cardiovascular disease (CVD) of anti-diabetic treatment which exert their effect by increasing the insulin sensitivity in patients with type 2 diabetes (T2D). In overweight T2D patients, it has been demonstrated that metformin reduces the CVD risk. The effect of glitazones on CVD is uncertain. There is insufficient evidence to support a protective effect on CVD of lowering blood-glucose per se. In contrast, lowering blood glucose appears to decrease the risk of microvascular complications.